A Phase I Safety and Tolerability Study of PP-001 Eye Drops in Healthy Adult Volunteers
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 19 Sep 2019
Price : $35 *
At a glance
- Drugs PP 001 (Primary)
- Indications Keratoconjunctivitis
- Focus Adverse reactions
- Sponsors Panoptes Pharma
- 19 Sep 2019 Planned End Date changed from 31 May 2019 to 1 Dec 2019.
- 19 Sep 2019 Planned primary completion date changed from 30 Apr 2019 to 1 Nov 2019.
- 19 Sep 2019 Status changed from recruiting to active, no longer recruiting.